Table 1.
Trial characteristics
| Study | Registration | Funding | Country | Mean age | % Male | Duration of migraine (years) | % Aura | Migraine days per month at baseline | Interventions | Number of patients |
|---|---|---|---|---|---|---|---|---|---|---|
| Couch 1979 [30] | NR | Merck Laboratories | US | NR | 16.0 | NR | NR | NR |
Amitriptyline 100 mg/day or MTD, titrated over 4 weeks, maintained for 4 weeks, oral Placebo |
100 |
| Couch 2011 [32] | NR | Merck, Sharp, and Dohme Research Laboratories | US | 34.9 | 19.0 | NR | NR | NR |
Amitriptyline 100 mg/day or MTD, titrated over 4 weeks, maintained for 12 weeks, oral Placebo |
391 |
| Gonçalves 2016 [33] | NCT 01357031 | Fundação de Amparo a Pesquisa de São Paulo | Brazil | 36.9 | 24.6 | 22.2 | 16.1 | 7.3 |
Amitriptyline 25 mg/day for 12 weeks Placebo |
131 |
NR not reported, NCT number clinical trial, MTD maximum tolerable dose